<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04665037</url>
  </required_header>
  <id_info>
    <org_study_id>5592-127</org_study_id>
    <secondary_id>2019-003842-34</secondary_id>
    <secondary_id>MK-5592-127</secondary_id>
    <nct_id>NCT04665037</nct_id>
  </id_info>
  <brief_title>Posaconazole (MK-5592) Intravenous and Oral in Children (&lt;2 Years) With Invasive Fungal Infection (MK-5592-127)</brief_title>
  <official_title>A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formulations in Pediatric Participants From Birth to Less Than 2 Years of Age With Possible, Probable, or Proven Invasive Fungal Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to estimate the pharmacokinetics (PK) of posaconazole (POS, MK-5592)&#xD;
      intravenous (IV) and powder for oral suspension (PFS) formulations in pediatric participants&#xD;
      &lt;2 years of age with invasive fungal infection (IFI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are 2 panels in this study. In Panel A, POS IV will be evaluated in ≥8 participants,&#xD;
      including ≥5 who are &lt;3 months of age and ≥3 who are 3 months to &lt;2 years of age. In Panel B,&#xD;
      both POS IV and POS PFS will be evaluated in ≥14 participants, including ≥3 who are &lt;3 months&#xD;
      of age and ≥5 who transition to the PFS formulation of POS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average concentration (Cavg) of single-dose IV POS (Panel A)</measure>
    <time_frame>Predose, 0.25 and 24 hours post-infusion on Day 1</time_frame>
    <description>The Cavg of IV POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) of single-dose IV POS (Panel A)</measure>
    <time_frame>Predose, 0.25 and 24 hours post-infusion on Day 1</time_frame>
    <description>The Cmax of IV POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum concentration (Tmax) of single-dose IV POS (Panel A)</measure>
    <time_frame>Predose, 0.25 and 24 hours post-infusion on Day 1</time_frame>
    <description>The Tmax of IV POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from dosing to 24 hours postdose (AUC0-24) of single-dose IV POS (Panel A)</measure>
    <time_frame>Predose, 0.25 and 24 hours post-infusion on Day 1</time_frame>
    <description>The AUC 0-24 of IV POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL) of single-dose IV POS (Panel A)</measure>
    <time_frame>Predose, 0.25 and 24 hours post-infusion on Day 1</time_frame>
    <description>The clearance (CL) of IV POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from dosing to infinity (AUC0-∞) of single-dose IV POS (Panel A)</measure>
    <time_frame>Predose, 0.25 and 24 hours post-infusion on Day 1</time_frame>
    <description>The AUC0-∞ of IV POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cavg of multiple-dose IV POS (Panel B)</measure>
    <time_frame>Predose and 0.25 post-infusion on Day 1; Weeks 1, 2, 4, 6, 9, and 12</time_frame>
    <description>The Cavg of IV POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of multiple-dose IV POS (Panel B)</measure>
    <time_frame>Predose and 0.25 post-infusion on Day 1; Weeks 1, 2, 4, 6, 9, and 12</time_frame>
    <description>The Cmax of IV POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of multiple-dose IV POS (Panel B)</measure>
    <time_frame>Predose and 0.25 post-infusion on Day 1; Weeks 1, 2, 4, 6, 9, and 12</time_frame>
    <description>The Tmax of IV POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 of multiple-dose IV POS (Panel B)</measure>
    <time_frame>Predose and 0.25 post-infusion on Day 1; Weeks 1, 2, 4, 6, 9, and 12</time_frame>
    <description>The AUC0-24 of IV POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL) of multiple-dose IV POS (Panel B)</measure>
    <time_frame>Predose and 0.25 post-infusion on Day 1; Weeks 1, 2, 4, 6, 9, and 12</time_frame>
    <description>The CL of IV POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ of multiple-dose IV POS (Panel B)</measure>
    <time_frame>Predose and 0.25 post-infusion on Day 1; Weeks 1, 2, 4, 6, 9, and 12</time_frame>
    <description>The AUC0-∞ of IV POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cavg of multiple-dose PFS POS (Panel B)</measure>
    <time_frame>Predose and 0.25 post-infusion on Day 1; Weeks 1, 2, 4, 6, 9, and 12</time_frame>
    <description>The Cavg of PFS POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of multiple-dose PFS POS (Panel B)</measure>
    <time_frame>Predose and 0.25 post-infusion on Day 1; Weeks 1, 2, 4, 6, 9, and 12</time_frame>
    <description>The Cmax of PFS POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of multiple-dose PFS POS (Panel B)</measure>
    <time_frame>Predose and 0.25 post-infusion on Day 1; Weeks 1, 2, 4, 6, 9, and 12</time_frame>
    <description>The Tmax of PFS POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 of multiple-dose PFSPOS (Panel B)</measure>
    <time_frame>Predose and 0.25 post-infusion on Day 1; Weeks 1, 2, 4, 6, 9, and 12</time_frame>
    <description>The AUC0-24 of PFS POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL) of multiple-dose PFS POS (Panel B)</measure>
    <time_frame>Predose and 0.25 post-infusion on Day 1; Weeks 1, 2, 4, 6, 9, and 12</time_frame>
    <description>The CL of PFS POS is based on population PK analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ of multiple-dose PFS POS (Panel B)</measure>
    <time_frame>Predose and 0.25 post-infusion on Day 1; Weeks 1, 2, 4, 6, 9, and 12</time_frame>
    <description>The AUC0-∞ of PFS POS is based on population PK analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cavg of IV POS in neonates and infants &lt;2 years of age compared to adults and older pediatric populations (Panel B)</measure>
    <time_frame>Predose and 0.25 post-infusion on Day 1; Weeks 1, 2, 4, 6, 9, and 12</time_frame>
    <description>The Cavg of IV POS is based on population PK analysis. Comparisons between participants in Panel B will be made to data that was previously collected in older participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with an ≥ 1 adverse event (AE)</measure>
    <time_frame>Up to 98 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who discontinued study therapy due to an AE</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a drug-related AE</measure>
    <time_frame>Up to 98 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with all-cause mortality (ACM) [Panel B]</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>The percentage of participants with ACM will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with need for systemic antifungal therapy (other than POS) during the study period (Panel B)</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>Percentage of participants who received additional antifungal therapy in Panel B will be reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Invasive Fungal Infection</condition>
  <arm_group>
    <arm_group_label>Panel A: POS IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Posaconazole 6 mg/kg body weight administered in a single dose by IV infusion on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B: POS IV/PFS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Posaconazole at a dose to be determined administered twice daily by IV infusion on Day 1, and then once daily from Day 2 to a maximum 84 days. Following a minimum of 7 days IV dosing, participants as clinically able will be transitioned from POS IV to POS PFS on Day 8, once daily to a maximum 84 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole IV 6 mg/kg</intervention_name>
    <description>POS 6 mg/kg of body weight by IV infusion in a single dose on Day 1</description>
    <arm_group_label>Panel A: POS IV</arm_group_label>
    <other_name>MK-5592</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole IV TBD</intervention_name>
    <description>POS at a dose to be determined (TBD) by IV infusion twice daily on Day 1; and then once daily on Day 2 to a maximum 84 days</description>
    <arm_group_label>Panel B: POS IV/PFS</arm_group_label>
    <other_name>MK-5592</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole PFS TBD</intervention_name>
    <description>POS at a dose TBD, orally by PFS starting on Day 8 once daily for a maximum 84 days</description>
    <arm_group_label>Panel B: POS IV/PFS</arm_group_label>
    <other_name>MK-5592</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Panel A: Is undergoing treatment for possible, probable, or proven IFI known or&#xD;
             suspected to be cause by fungal pathogens against which POS has demonstrated activity&#xD;
             (which can include candidiasis)&#xD;
&#xD;
          -  Panel B: has a diagnosis of possible, probable, or proven IFI known or suspected to be&#xD;
             cause by fungal pathogens against which POS has demonstrated activity (and cannot&#xD;
             include candidiasis)&#xD;
&#xD;
          -  If enrolled with a possible or probable IFI diagnosis, has one or more of the listed&#xD;
             host factors&#xD;
&#xD;
          -  If enrolled with a possible or probable IFI diagnosis, meets listed criteria&#xD;
&#xD;
          -  If enrolled with a proven IFI diagnosis, sampling of normally sterile tissue has shown&#xD;
             fungal elements by cytology or microscopy, or sampling of normally sterile tissue or&#xD;
             blood has yielded a positive culture for a fungal pathogen&#xD;
&#xD;
          -  Has clinical symptoms consistent with an acute episode of IFI, defined as duration of&#xD;
             clinical syndrome of &lt;30 days.&#xD;
&#xD;
          -  Has a central line (eg, central venous catheter, peripherally-inserted central&#xD;
             catheter) in place or planned to be in place before beginning IV study intervention.&#xD;
&#xD;
          -  Has a body weight of ≥500 g&#xD;
&#xD;
          -  The participant (or legally acceptable representative) has provided documented&#xD;
             informed consent for the study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Has received POS within 30 days before Day 1&#xD;
&#xD;
          -  Has cystic fibrosis, pulmonary sarcoidosis, aspergilloma, or allergic bronchopulmonary&#xD;
             aspergillosis.&#xD;
&#xD;
          -  Has a known hereditary problem of galactose intolerance, Lapp lactase deficiency, or&#xD;
             glucose-galactose malabsorption&#xD;
&#xD;
          -  Has known or suspected active COVID-19 infection&#xD;
&#xD;
          -  Has chronic (≥30 days' duration) IFI, relapsed/recurrent IFI, or refractory IFI that&#xD;
             has not responded to prior antifungal treatment&#xD;
&#xD;
          -  Has a known hypersensitivity or other serious adverse reaction to any azole antifungal&#xD;
             therapy, or to any other ingredient of the study intervention used&#xD;
&#xD;
          -  Has any known history of torsade de pointes, unstable cardiac arrhythmia or&#xD;
             proarrhythmic conditions, a history of recent myocardial infarction, congenital or&#xD;
             acquired QT interval (QT) prolongation, or cardiomyopathy in the context of cardiac&#xD;
             failure within 90 days of first dose of study intervention&#xD;
&#xD;
          -  Has known or suspected Gilbert disease&#xD;
&#xD;
          -  Has received any listed prohibited medications within the specified timeframes before&#xD;
             the start of study intervention&#xD;
&#xD;
          -  Has a known hereditary problem of galactose intolerance, Lapp lactase deficiency, or&#xD;
             glucose-galactose malabsorption (Part B)&#xD;
&#xD;
          -  Has invasive candidiasis (Part B)&#xD;
&#xD;
          -  Has enrolled previously in the current study and been discontinued&#xD;
&#xD;
          -  Has QTc prolongation at screening &gt;500 msec&#xD;
&#xD;
          -  Has significant liver dysfunction&#xD;
&#xD;
          -  Is hemodynamically unstable, exhibits hemodynamic compromise, or is not expected to&#xD;
             survive at least 5 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rady Children's Hospital-San Diego ( Site 2101)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>858-966-8381</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital ( Site 2109)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>784-624-3529</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago ( Site 2104)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>312-227-6280</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center ( Site 2106)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-668-4736</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Driscoll Children's Hospital ( Site 2113)</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>361-694-5978</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gent ( Site 1052)</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3293324986</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Athens Childrens Hospital Aglaia Kyriakou ( Site 1102)</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+306973973179</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki &quot;Ippokrateio&quot; ( Site 1100)</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 42</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>306937442644</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 1402)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247774512</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Hebrew University Medical Center ( Site 1401)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226777111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center ( Site 1403)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97236974521</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Neoplasicas ( Site 1601)</name>
      <address>
        <city>Lima</city>
        <zip>15038</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5112016500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital Dzieciecy ( Site 1705)</name>
      <address>
        <city>Olsztyn</city>
        <state>Warminsko-mazurskie</state>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0048895393370</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mechnikov State Medical University ( Site 1803)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78123035146</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pavlov State Medical University ( Site 1801)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78123386239</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Children Clinical Hospital 1 ( Site 1802)</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Sverdlovskaya Oblast</state>
        <zip>620149</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+783432319120</phone>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Greece</country>
    <country>Israel</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

